Replay available

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Q3 2020 Earnings Call

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) Q3 2020 earnings conference call, held 2020-11-10. Replay captured from the company's public earnings webcast.

Tue, November 10, 2020 at 8:30 AMendedReplay
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Q3 2020 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Ted Jenkins

Senior Director, Investor Relations and Corporate Communications

Dr. Yuval Cohen

Chief Executive Officer

Dr. Barbara White

Chief Medical Officer and Head of Research

Brian Abrams

Analyst, RBC Capital Markets

Kenny Chanon

Analyst, Jefferies (for Murray Raycroft)

Layling Gersher

Analyst, Oppenheimer

Replay transcript excerpt

Hello and welcome to the Corbett Pharmaceuticals third quarter November 10th, 2020 earnings conference call. As a brief reminder, all participants are currently in a listen-only mode. If anyone requires operator assistance during a conference, please press star zero on your telephone keypad. Following the presentation, there will be a question and answer session. Do note that this conference is being recorded at company's request and will be made available on the company's website following the end of the call. I will now turn the conference over to your host, Ted Jenkins, Senior Director, Investor Relations and Corporate Communications. Please go ahead, sir. Thank you, Operator, and good morning, everyone. Thank you for joining us today. At this time, I'd like to remind our listeners that remarks made during this call state management's intentions, hopes, beliefs, expectations, or projections of the future. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the Federal Security's laws. These forward-looking statements are based on Corpus' current expectations, and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from those contemplated by such forward-looking statements are discussed in the periodic reports Corpus files with Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. Joining me on the call today are Dr. Yuval Cohen, our Chief Ex...

More from Corbus Pharmaceuticals Holdings, Inc.